Dear Dermoscopists,

We are pleased to introduce you to the project “e-Learning Short Courses”, with the aim to facilitate the fast comprehension of new dermoscopic concepts. This material is designed to be practical and help you in your daily routine.
Progressively, a number of eLearning Short Courses will be available in open-access to the eLearning Esclerosis Múltiple (EM) members on the web with a self-evaluation test. We hope that this will be a great time for you!

Josep Malvehy
Coordinator of the e-Learning Short Courses



Our courses are devised by internationally renowned specialists. They are addressed to physicians as well as other health professionals. These professionals can range from highly skilled experts to those health professionals still under training.

Our courses are provided in electronic and multimedia version. They consist of several video lessons, that is, pre-recorded lessons, all of them accompanied by in-sync medical slides for illustrative purposes. As additional material, we present an abstract (summary) of the lesson content in audio or text (PDF) version. This includes bibliographical References and any links that might be of interest.

Each course ends with an assessment test. Participants must pass said test to have a Diploma with credits

If you want to attend any of our courses, you must be subscribed. Thus, you must choose the course you wish to attend, by clicking on “Subscribe”. Then, while subscribing you will be asked if you have ever subscribed to any of our courses. If your answer is “no”, the menu will take to the subscription form. Please, fill it out to have your access codes to the course (your email and password). This form shall only be completed once so that you can access your first course after you complete your online subscription. Once subscribed, your codes (username [your email] and password) will serve as access to any of our e-Learning courses.

How to access any other course
Simply select a course by clicking on “Subscribe”. The subscription process is just the same. You will be asked: “Have you ever subscribed to any of our courses?” As this is not your first course, the system will recognize you: you should answer “yes”. Then, you just have to log in with your username [email] and password to access the menu (“Access”).

How to access “My Class”
Once you are subscribed, you will access a customized area called “My Class” (the student’s lesson). There you will find all the information regarding the courses you are subscribed to. You can access them, by continuing with the video lessons and take the respective self-assessment tests. In addition, you can download the Certificate or Diploma. Your academic data will be saved in “My Class”, where you can refer to all the courses you have taken, with your results. 

You can also access your profile and change your data if required. Once you log out, you can log in to “My Class” from the “Access My Class” option, by simply logging in with your username and password in the “Access My Class” section.

How to take the course
Each course addresses a topic and is divided into several lessons. These are pre-recorded video lessons taught by a medical doctor and teacher and are accompanied by PowerPoint slides. The slides illustrate the explanations and are presented in-sync with the video. You can take the course at your own pace, by pausing and resuming it as often as it suits you.

Moreover, you will also find an abstract (summary) of the course, references recommended by the teacher (bibliography) and a self-assessment test with practical questions on the content. If you answer the test correctly (a score of 70% correct answers is mandatory), you can download the accredited Diploma.

How to do the test
The test is a standard multiple-choice questions (MCQ) test. You must mark only one answer for each question. You should answer all the questions.

You can do the test at your own pace. The system allows you to “Save” an unfinished version of the test and resume it at any other time, as often as it suits you. You can always retrieve the test in the “Test” section (it stores the last version saved).

Once you click on “Send”, the test is finished and you will know for once that you may not change or correct any of your answers. You will immediately know if you have passed or failed the test, and you will be able to compare your test answers with the correct answers and the teacher’s comments.

You have two chances to pass the test and obtain the Diploma. If you do not pass the first test, you can do it again and then, have another chance to pass.

Diploma and credits
You must pass the test to have the Diploma which will be converted in credits. Once you pass, you can download your Certificate, which is also available in the student’s private session (“My Class”)

Satisfaction survey
Once you have successfully completed the course, you can take our satisfaction survey. The information supplied by you will help us improve our courses’ content and keep up with the quality of the programme.

Software and hardware requirements
Internet Explorer 8.x or later versions, Mozilla Firefox or Chrome.

Our courses require additional software to view their multimedia content, the teacher’s lessons and the printable versions of the materials. Therefore, you can access the following link:

Some mobile devices display the videos on a fullscreen format, which prevents simultaneous viewing of in-sync slides. This is due to the own settings of your device and is unrelated to our website settings. 




To inscribe

To participate in a course you must be previously subscribed, completing the form to get your Access codes. These (E-mail and password) are valid to access any of the courses on the Web page.
To inscribe in a new course, you have to select it and introduce again your user name and password in the Inscription Menu.
If after 8 months following the date of the inscription you have not participated in the course, your Access codes (E-mail and password) will expire automatically and you will have to re-inscribe to the course.

To participate in the courses

Once subscribed and inscribed, you will have available a personal page or student's Classroom. The Classroom contains the information on the courses to which you are subscribed. From here you can complete the lessons and questionnaires in sequence.
Each course is a session on a theme, comprising three modules. Each of these is accompanied by a video synchronized with descriptive PowerPoint slides. 
In addition, you will find an Abstract of the course (pdf document) and a self-evaluation questionnaire with practical questions about the content.
Having successfully answered all the questions of the three modules (with a maximum of 2 fails), you will be able to download an accreditation Diploma of the course.

To complete the questionnaires

Each questionnaire consists in a variable number of multiple choice questions. For each question you must mark only one of the possible answers. You must answer all the questions. If necessary, you can 'save' the uncompleted questionnaire and return to complete it at a later date, as many times as you like. You can retrieve the incomplete questionnaire in your course page, with the completed and outstanding questions just as you saved it. Once you have sent the questionnaire, you are not permitted to do any correction to your answers. In case you have not pass the test, you can download a PDF file with author's commentaries to the questions and try it again. You must pass the test to obtain the Diploma with credits.

European Accreditation Council for Continuing Medical Education

The “Dermoscopic diagnosis of Actinic Keratosis and Squamous Cell Carcinoma”, made available on and organized by EM eLearning Esclerosis Múltiple (EM) and Permanyer, is awarded 1 European CME credits (ECMEC's).

The European Accreditation Council for Continuing Medical Education (EACCME) was set up by the UEMS for the purpose of ensuring the international mutual recognition of quality assessments of CME-CPD activities organised all over the world for the benefit of European doctors.

Your academic history

In the student's page, you will be able to see the courses that you are inscribed to, the completed courses, and the questionnaires you have filled in.


  • On-Demand Webcast - eLearning


    Dr. Delvys Rodríguez Abreu

    Oncology Unit
    Hospital Universitario Insular
    Las Palmas de Gran Canaria, Spain 

    Director of the lung cancer and melanoma unit and early clinical development programs, he participates in the clinical research of new biomarkers and targeted molecular therapy in lung cancer. He is an active member of the Spanish Society of Medical Oncology (SEOM) and the European Society of Oncology (ESMO). He has published dozens of peer-reviewed articles, as well as book chapters.

    Dr. Oscar Arrieta


    Dr. Óscar Arrieta

    Thoracic Oncology Unit
    Instituto Nacional de Cancerología de México (INCAN)

    His research activities include evaluating predictive and prognostic markers for the treatment of lung cancer and mesothelioma, as well as developing new treatment schemes for thoracic tumours and brain metastases, and evaluating the quality of life of patients with these tumours. He is actively engaged in the design and coordination of clinical trials and is the national coordinator of treatment guidelines for non-small cell lung cancer.


    Lung cancer is the leading cause of cancer-related deaths worldwide1,2. Nearly 85% of patients with lung cancer will present with non-small cell lung cancer (NSCLC). This disease has certain variations that differ for each patient concerning their treatment. Nowadays, this is known as 'personalized medicine'.

    Immunotherapy is undoubtedly part of the standard treatment for NSCLC in stages III and IV. Treatment of stage IV NSCLC with second-line immunotherapy with new drugs improves response rates, OS, and HR, in addition to increased long-term survival.

    New options have shown positive results as a first-line treatment, both as monotherapy and in combination with chemotherapy, in patients with stage IV NSCLC. Combinations under study with chemotherapy are an option that improves PFS and OS in patients, in general, and in the subgroup of patients with high tumour burden. Notwithstanding, it is necessary to identify predictive efficacy and toxicity factors in order to personalize the treatment and design clinical trials that help answer clinically relevant questions that arise as new treatments appear.3,9.

    In this activity, we review the clinical experience and new challenges posed by optimal therapeutic management with immunotherapy in patients with lung cancer, as well as the status of lung cancer and COVID-19 in Mexico.

    1. Avrillon V, Pérol M. Alectinib for treatment of ALK-positive non-small-cell lung cancer. Future Oncol. 2017;13(4):321-35.

    2. Hoang T, Myung SK, Pham TT, Park B. Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials. Cancers (Basel). 2020;12(3).

    3. Jotte RM, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodriguez Abreu D, Hussein MA, et al. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin

    + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol. 2018;36(suppl 18) [abstract LBA9000

    4, Barlesi F, Nishio M, Cobo M, Steele N, Paramonov V, Parente B, et al. IMpower132: efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC). Ann Oncol. 2018;29(suppl 8) [abstract LBA54].

    5. Socinski MA, Jotte RM, Cappuzzo F, Jorquera Orlandi F, Stroyakovskiy D, Nogami N, et al. Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. J Clin Oncol. 2018;36(Suppl 15) [abstract 9002].

    6. Herbst RS, Garon EB, Kim D, Chul Cho B, Pérez Garcia JL, Han J, et al. Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro. Ann Oncol. 2018;29(suppl 10) [abstract LBA63].

    7. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Cs szi T, Fül.p A, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537-46.

    8. Rizvi NA, Chul Cho B, Reinmuth N, Lee KH, Ahn M, Luft A, et al. Durvalumab with or without tremelimumab vs platinum based chemotherapy as firstline treatment for metastatic non-small cell lung cancer: MYSTIC. Ann Oncol. 2018;29(suppl 10) [abstract LBA6].

    9. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-39.



    This webcast has been designed solely for medical education purposes and for the cancer community. It is endorsed by the Mexican Society of Oncology (SMEO) and bears a four-point certification by the Mexican Council of Oncology (CMO), with a 70% pass rate at the self-evaluation questionnaire.

    Release Date: May 2020 

    Closing Date: July 2020



    You can access questionnaire after completing the registration process, on a PC, Mac or mobile phone, with updated versions of the Internet Explorer, Mozilla Firefox, Google Chrome or Safari browsers. Please direct your technical questions to



    This activity has been developed with an independent educational grant from ROCHE. According to Permanyer's disclosure policy, teachers, moderators and / or anyone directly related to the production of this webcast must report any relevant financial relationship with commercial companies or public institutions, as well as any potential conflict of interest. Any existing interest or relationship does not imply bias or decrease the value of the presentation.



    This activity is presented as a service to the medical profession. Its content reflects the opinions, criteria and / or findings and conclusions of the authors, who are responsible for the statements. In this activity, dosage guidelines other than those approved in the corresponding Prescribing Information (IPP) may be cited. Some of the references that are made on the use and / or dispensing of pharmaceutical products, may not be entirely in accordance with those references approved by the competent Health Authorities, so we recommend referring to them. The course teachers, the sponsor and Permanyer, always recommend the use of the products in accordance with the IPP approved by the Health Authorities.



    By registering for this activity, your data will be stored into the "e-Learning Users" file, created by P.Permanyer, S.L. in order to organize and manage this online training service, as well as for information, monitoring and accreditation purposes of the training activities. Your personal data will be shared with collaborating companies and entities, as well as with entities associated with the training activities to which you subscribe. The identification of these companies and entities appears within the activity information. By voluntarily supplying your personal data by any form on this website or by sending an email, P. Permanyer S.L. understands that you expressly authorize the processing of your data for the abovementioned purposes. In addition, you consent to receive information about their products or services by mail or electronic mail. P.Permanyer, S.L. has adopted the necessary technical measures to avoid the alteration, loss or unauthorized processing of any personal data that you may supply and restates its commitment to confidentiality regarding the processing of your personal data.

    You have the right to access any information of your concern, request its rectification, delete it or oppose its processing by sending an email addressed to, or by regular mail addressed to the address listed in this legal notice. In both cases, your identification details may be required.